Get started
Author

Simona Rizzi

ORCID: 0000-0002-1515-2096
Observed ORCID: 0000-0002-1515-2096
OpenAlex ID: A5087080299
Covalent and allosteric inhibitors of the ATPase VCP/p97 induce cancer cell death
2013 · Paola Magnaghi, Roberto D'Alessio, et al. · Nature Chemical Biology · 383
NMS-P937, an Orally Available, Specific Small-Molecule Polo-like Kinase 1 Inhibitor with Antitumor Activity in Solid and Hematologic Malignancies
2012 · Barbara Valsasina, Italo Beria, et al. · Molecular Cancer Therapeutics · 128
Alkylsulfanyl-1,2,4-triazoles, a New Class of Allosteric Valosine Containing Protein Inhibitors. Synthesis and Structure–Activity Relationships
2012 · Paolo Polucci, Paola Magnaghi, et al. · Journal of Medicinal Chemistry · 95
Redundancy of autocrine loops in human osteosarcoma cells
1999 · Stefania Benini, Nicola Baldini, et al. · International Journal of Cancer · 88
PDF
An antibody-drug conjugate directed to the ALK receptor demonstrates efficacy in preclinical models of neuroblastoma
2019 · Renata Sano, Kateryna Krytska, et al. · Science Translational Medicine · 70
PDF
Phosphorylation of TCTP as a marker for polo-like kinase-1 activity in vivo.
2010 · Ulisse Cucchi, Laura M Gianellini, et al. · PubMed · 60
Discovery of 2-(Cyclohexylmethylamino)pyrimidines as a New Class of Reversible Valosine Containing Protein Inhibitors
2014 · Giovanni Cervi, Paola Magnaghi, et al. · Journal of Medicinal Chemistry · 22
Novel Thienoduocarmycin–Trastuzumab ADC Demonstrates Strong Antitumor Efficacy with Favorable Safety Profile in Preclinical Studies
2023 · Barbara Valsasina, Paolo Orsini, et al. · Molecular Cancer Therapeutics · 6
Abstract 734: Thienoindoles: New highly promising agents for antibody-drug conjugates generation
2018 · Michele Caruso, Fabio Gasparri, et al. · Cancer Research · 4
Abstract 822: Thienoindoles, a novel class of DNA minor groove alkylating agents highly suited for the generation of novel antibody drug conjugates (ADCs)
2014 · Barbara Valsasina, Fabio Gasparri, et al. · Cancer Research · 2
Abstract 5805: A novel platform of diversified payloads to drive ADC innovation
2024 · Paolo Orsini, Matteo Salsa, et al. · Cancer Research · 1
Abstract 5163: Characterization of NMS-E194, a selective and potent PERK inhibitor with efficacy in the KMS-11 multiple myeloma
2017 · Claudia Perrera, Maurizio Pulici, et al. · Cancer Research · 1
Abstract 2690: A novel antibody-drug conjugate directed to the ALK receptor tyrosine kinase demonstrates efficacy in models of neuroblastoma
2016 · Renata Sano, Kateryna Krytska, et al. · Cancer Research · 1
Abstract 2940: Identification of potent VCP/p97/CDC48 inhibitors with distinct biochemical mechanisms including a reversible, allosteric inhibitor that activates the unfolded protein response, induce autophagy and cancer cell death
2012 · Paola Magnaghi, Roberto D'Alessio, et al. · Cancer Research · 1
Table S5 from Novel Thienoduocarmycin–Trastuzumab ADC Demonstrates Strong Antitumor Efficacy with Favorable Safety Profile in Preclinical Studies
2023 · Barbara Valsasina, Paolo Orsini, et al.
Table S6 from Novel Thienoduocarmycin–Trastuzumab ADC Demonstrates Strong Antitumor Efficacy with Favorable Safety Profile in Preclinical Studies
2023 · Barbara Valsasina, Paolo Orsini, et al.
Data from Novel Thienoduocarmycin–Trastuzumab ADC Demonstrates Strong Antitumor Efficacy with Favorable Safety Profile in Preclinical Studies
2023 · Barbara Valsasina, Paolo Orsini, et al.
Figure S2 from Novel Thienoduocarmycin–Trastuzumab ADC Demonstrates Strong Antitumor Efficacy with Favorable Safety Profile in Preclinical Studies
2023 · Barbara Valsasina, Paolo Orsini, et al.
Figure S3 from Novel Thienoduocarmycin–Trastuzumab ADC Demonstrates Strong Antitumor Efficacy with Favorable Safety Profile in Preclinical Studies
2023 · Barbara Valsasina, Paolo Orsini, et al.
Table S2 from Novel Thienoduocarmycin–Trastuzumab ADC Demonstrates Strong Antitumor Efficacy with Favorable Safety Profile in Preclinical Studies
2023 · Barbara Valsasina, Paolo Orsini, et al.
Table S3 from Novel Thienoduocarmycin–Trastuzumab ADC Demonstrates Strong Antitumor Efficacy with Favorable Safety Profile in Preclinical Studies
2023 · Barbara Valsasina, Paolo Orsini, et al.
Table S2 from Novel Thienoduocarmycin–Trastuzumab ADC Demonstrates Strong Antitumor Efficacy with Favorable Safety Profile in Preclinical Studies
2023 · Barbara Valsasina, Paolo Orsini, et al.
Table S1 from Novel Thienoduocarmycin–Trastuzumab ADC Demonstrates Strong Antitumor Efficacy with Favorable Safety Profile in Preclinical Studies
2023 · Barbara Valsasina, Paolo Orsini, et al.
Table S4 from Novel Thienoduocarmycin–Trastuzumab ADC Demonstrates Strong Antitumor Efficacy with Favorable Safety Profile in Preclinical Studies
2023 · Barbara Valsasina, Paolo Orsini, et al.
Data from Novel Thienoduocarmycin–Trastuzumab ADC Demonstrates Strong Antitumor Efficacy with Favorable Safety Profile in Preclinical Studies
2023 · Barbara Valsasina, Paolo Orsini, et al.
Works count: 36
Citation count: 862
H-index: 7
I10-index: 7
Year
Topic
Type